Impact of Diabetes on Long-term Survival in Elderly Liver Cancer Patients: A Retrospective Study

Overview

Journal Open Med (Wars)

Date 2025 Jan 17

PMID 39822990

Authors

Dan Chen

Xiaoxiao Gao

Yaqing Wang

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Liver cancer is a prevalent and life-threatening condition, particularly among elderly individuals. The association between diabetes, a chronic metabolic disorder, and the onset and advancement of liver cancer has been widely acknowledged. However, the effect of diabetes on the survival of older patients with liver cancer has been a topic of debate. In light of this, we undertook a retrospective study to assess the impact of diabetes on the overall survival (OS) of elderly individuals diagnosed with liver cancer.

Methods: In this retrospective analysis, we examined clinical data from liver cancer patients aged 80 years or older who underwent diagnosis and treatment at a solitary medical center from January 2010 to December 2019. Comprehensive records encompassing baseline information, treatment protocols, diabetes history, and mortality during follow-up were meticulously documented. Employing the Kaplan-Meier method and the Cox proportional hazards model, we sought to assess the influence of diabetes on both the OS and recurrence-free survival (RFS) in elderly individuals diagnosed with liver cancer.

Results: This study comprised 244 elderly liver cancer patients, with 68 individuals reporting a history of diabetes. In the unadjusted Kaplan-Meier survival analysis, the diabetes group exhibited a lower OS compared to the non-diabetes group. Utilizing a multivariate Cox proportional hazards model, diabetes emerged as a prognostic factor influencing OS (hazard ratio, HR = 1.782 [1.163-2.743], = 0.043). Regarding RFS, unadjusted Kaplan-Meier analysis revealed a diminished RFS in the diabetes group compared to the non-diabetes group. In the multivariate Cox proportional hazards model, diabetes remained a significant prognostic factor impacting RFS (HR = 1.742 [1.083-1.546], = 0.041).

Conclusion: Our study indicates a significant impact of diabetes on both OS and RFS among elderly liver cancer patients. These insights may contribute to more precise guidance and recommendations for the treatment of this specific demographic, offering valuable information for healthcare practitioners working with elderly individuals diagnosed with liver cancer.

References

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

Huo T, Wu J, Lui W, Lee P, Huang Y, Chau G . Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol. 2003; 15(11):1203-8. DOI: 10.1097/00042737-200311000-00009. View

Angulo P, Keach J, Batts K, Lindor K . Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-62. DOI: 10.1002/hep.510300604. View

Mori K, Nishide K, Okuno S, Shoji T, Emoto M, Tsuda A . Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. BMC Nephrol. 2019; 20(1):105. PMC: 6437886. DOI: 10.1186/s12882-019-1271-8. View

Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y . Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2011; 130(7):1639-48. DOI: 10.1002/ijc.26165. View

Li X, Xu H, Gao Y, Pan M, Wang L, Gao P . Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine (Baltimore). 2017; 96(13):e6508. PMC: 5380289. DOI: 10.1097/MD.0000000000006508. View

Ali G, Omar H, Hersi F, Abo-Youssef A, Ahmed O, Mohamed W . The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene- Induced Hepatocarcinogenesis in Wistar Rats: The Impact of NF-κB/COX-2/PGE2 Signaling. Curr Mol Pharmacol. 2021; 15(1):252-262. DOI: 10.2174/1874467214666210708103752. View

Xing M, Wang X, Kiken R, He L, Zhang J . Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. Int J Mol Sci. 2021; 22(11). PMC: 8201127. DOI: 10.3390/ijms22116139. View

Marengo A, Rosso C, Bugianesi E . Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2015; 67:103-17. DOI: 10.1146/annurev-med-090514-013832. View

10.

Anwanwan D, Singh S, Singh S, Saikam V, Singh R . Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188314. PMC: 6981221. DOI: 10.1016/j.bbcan.2019.188314. View

11.

Arnold M, Pandeya N, Byrnes G, Renehan P, Stevens G, Ezzati P . Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2014; 16(1):36-46. PMC: 4314462. DOI: 10.1016/S1470-2045(14)71123-4. View

12.

El-Serag H, Kanwal F . Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology. 2014; 60(5):1767-75. PMC: 4211957. DOI: 10.1002/hep.27222. View

13.

Kramer J, Natarajan Y, Dai J, Yu X, Li L, El-Serag H . Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2021; 75(6):1420-1428. PMC: 9107529. DOI: 10.1002/hep.32244. View

14.

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

15.

Onikanni S, Lawal B, Bakare O, Ajiboye B, Ojo O, Farasani A . Cancer of the Liver and its Relationship with Diabetes mellitus. Technol Cancer Res Treat. 2022; 21:15330338221119743. PMC: 9772979. DOI: 10.1177/15330338221119743. View

16.

Wang P, Kang D, Cao W, Wang Y, Liu Z . Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2011; 28(2):109-22. DOI: 10.1002/dmrr.1291. View

17.

Wang W, Wei C . Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020; 7(3):308-319. PMC: 7452544. DOI: 10.1016/j.gendis.2020.01.014. View

18.

Michelotti G, Machado M, Diehl A . NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013; 10(11):656-65. DOI: 10.1038/nrgastro.2013.183. View

19.

Sanyal A, Banas C, Sargeant C, Luketic V, Sterling R, Stravitz R . Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43(4):682-9. DOI: 10.1002/hep.21103. View